Hypertension and CHD risk: Whither alpha-1 blockers?

Indian Heart Journal

Volumn 48, Issue 3, 1996, Pages 265-271

  Pandit, R B ^a,b  

^a Department of Cardiology   (India)

^b Railway Hospital   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ACEBUTOLOL; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ATENOLOL; DOXAZOSIN; ENALAPRIL; HYDROCHLOROTHIAZIDE; PRAZOSIN; PROPRANOLOL; TERAZOSIN;

DIABETES MELLITUS; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; REVIEW; RISK FACTOR; SMOKING;

ADRENERGIC ALPHA-ANTAGONISTS; ANTIHYPERTENSIVE AGENTS; CORONARY DISEASE; GLUCOSE; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; LIPID METABOLISM; RISK FACTORS;

EID: 0030056638     PISSN: 00194832     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. McVeigh GE, Flack J, Grimm R. Goals of antihypertensive therapy. Drugs 1995; 49: 161-175
2. Neaton JD, Grimm RH, Prineas RJ, et al. Treatment of mild hypertension study. Final results. JAMA 1993; 14: 143-158
3. Lichtenstein MJ, Shipley MJ, Rose C. Systolic and diastolic blood pressures as predictors of coronary heart disease mortality in the Whitehall study. BMJ 1985; 291: 243-245
4. Dzau VJ. Mechanism of interaction of hypertension and hypercholesterolemia in atherogenesis: the effects of antihypertensive agents. Am Heart J 1988; 116: 1725-1728
5. Castelli WP. Epidemiology of coronary heart disease: the Framingham study. Am J Med 1984; 76(2A): 4-12
6. Caselli WP, Anderson K. A population at risk: prevalence of high cholesterol levels in hypertensive patients in the Framingham study. Am J Med 1986; 80(Suppl 2A): 23-32
7. Lipid Research Clinics Program. The Lipid Research Clinics coronary primary prevention trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984; 251: 351-364
8. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia: safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987; 317: 1237-1245
9. Weinberger MH. Optimizing cardiovascular risk reduction during antihypertensive therapy. Hypertension 1990; 16: 201-211
10. Krone W, Nagele H. Effects of antihypertensives on plasma lipids and lipoprotein metabolism. Am Heart J 1988; 116-1729-1734
11. Kannel WB, McGee DL, Castelli WP. Latest perspective on cigarette smoking and cardiovascular disease: the Framingham study. J Card Rehabil 1984; 4: 267-277
12. Samuleson O, Wilhelmsen L, Elmfeldt D, et al. Predictors of cardiovascular morbidity in treated hypertension: results from the Primary Prevention Trial in Goteberg, Sweden. J Hypertens 1985; 3: 167-176
13. IPPPSH Collaborative Group Cardiovascular risk and risk factors in a randomized trial of treatment based on the beta-blocker oxprenolol, the International Prospective Primary Prevention Study in Hypertension (IPPPSH). J Hypertens 1985; 3: 379-392
14. Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. BMJ 1985; 291: 97-104
15. Feher M. Antihypertensive drugs and the hypertensive diabetic patient. J Hum Hypertens 1990; 4(Suppl 3): 7-9
16. United Kingdom Prospective Diabetes Study III. Prevalence of hypertension and hypotensive therapy in patients with newly diagnosed diabetes: a multicenter study. Hypertension 1985; 7(Suppl II): II 8-II 13
17. The Working Group on Hypertension in Diabetes. Statement on hypertension in diabetes mellitus. Arch Intern Med 1987; 147: 830-842
18. Kannel WB. The epidemiology of impaired glucose tolerance and hypertension. Abstract of the paper presented at the symposium States of insulin resistance. The interaction between hypertension, glucose intolerance, and CHD. Montreal, Canada, June 1990, published by Adelphi Communications
19. Houston MC. Treatment of hypertension in diabetes mellitus. Am Heart J 1989; 118: 819-829
20. Baba T, Neugebauer S. The link between insulin resistance and hypertension. Effects of antihypertensive and hyperlipidaemic drugs on insulin sensitivity. Drugs 1994; 47: 383-404
21. Baba T, Kodama T, Ishizaki T. Effect of chronic treatment with enalapril on glucose tolerance and serum insulin response to glucose load in non-insulin resistant Japanese patients with essential hypertension. Eur J Clin Pharmacol 1993; 45: 23-27
22. Colucci WS. New developments in alpha-adrenergic receptor pharmacology: implications for the initial treatment of hypertension. Am J Cardiol 1983; 51; 639-643
23. Forte V, Ciampini M. Prazosin's antihypertensive activity in outpatients: an Italian multicenter study in general practice. Acta Thera 1978; 4; 299-311
24. Medical Department, Pfizer U.K. Data on file, Pfizer India, 1977/78
25. Fulton B, Wagstaff AJ, Sorkin EM. Doxazosin. An update of its clinical pharmacology and therapeutic applications in hypertension and benign prostatic hyperplasia. Drugs 1995; 49: 295-320
26. Leren P, Foss PO, Helgeland A, et al. Effect of propranolol and prazosin on blood lipids. The Oslo study. Lancet 1980; 2: 4-6
27. Scafers RF, Reid JL. Alpha blockers. In: Kaplan NM, Brenner BM, Laragh J, eds. New Therapeutic Strategies in Hypertension. Raven Press 1989
28. Neusy A-J, Lowenstein J. Effects of prazosin, atenolol, and thiazide diuretic on plasma lipids in patients with essential hypertension. Am J Med 1986; 80(Suppl 2A): 94-99
29. Takabatake T, Ohta M, Maekawa M, et al. Effects of long-term prazosin therapy on lipoprotein metabolism in hypertensive patients. Am J Med 1984; 76(Suppl 2A). 113-116
30. Goto Y. Selective alpha-1 inhibition and clinical management of hypertension with consideration of coronary heart disease risk factors: results of a multicenter trial in Japan. Clin Thera 1987; 9(Suppl D): 46-57
31. Stamler R, Stamler J, Gosch FC, Berkson DM, Dyer A, Hershinow P. Initial antihypertensive drug therapy: alpha blocker or diuretic. Interim report of a randomized, controlled trial. Am J Med 1986; 80(Suppl 2A): 90-93
32. Farsang C, Peter M, Balas-Eltes A, Feher J. Prazosin improves atherogenic index and inhibits the deleterious effect of dihydrochlorothiazide in patients with essential hypertension. J Cardiovasc Pharmacol 1987; 10(Suppl 12): 240-243
33. Goto Y, Tanabe T, Ogasawara Y, Takei Y, et al. The effects of prazosin and propranolol in combination with thiazide diuretics on blood pressure and serum lipids: a multicentre study. Eur J Clin Pharmacol 1987; 33: 339-344
34. Rouffy J, Jaillard J. Effects of two antihypertensive agents on lipids, lipoproteins, and apoproteins A and B. Am J Med 1986; 80(S 2A): 100-103
35. Titmarsh S, Monk JP. Terazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in essential hypertension. Drugs 1987; 33: 461-477
36. Barbieri C, Ferrari C, Borzio M, Piepoli V, Caldara R. Metabolic effects of chronic prazosin treatment. Horm Metab Res 1980; 12: 331-334
37. Swislocki ALM, Hoffman BB, Sheu WHH, Ida Chen YD, Reaven GM Effect of prazosin treatment on carbohydrate and lipoprotein metabolism in patients with hypertension. Am J Med 1989; 86(Suppl 1B): 14-18
38. Pollare T, Lithell H, Selinus I, Berne C. Application of prazosin is associated with an increase of insulin sensitivity in obese patients with hypertension. Diabetologia 1988; 31: 415-420
39. Levy P. Effects of prazosin on blood pressure and diabetic control in patients with type II diabetes mellitus and mild essential hypertension. Am J Med 1989; 86(Suppl 1B): 59-62
40. Leenen FHH, Smith DL, Farkas RM, et al. Vasodilators and regression of left ventricular hypertrophy: hydralazine versus prazosin in hypertensive humans. Am J Med 1987; 82: 969-978
41. Antani JA. Prazosin in hypertension with heart failure. J Cardiovasc Pharmacol 1979; 1(Suppl 6): S56-S62